Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright lowered their Q2 2025 earnings estimates for shares of Aquestive Therapeutics in a research note issued on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.22) per share for the quarter, down from their prior forecast of ($0.15). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics' Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.82) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.75) EPS.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million for the quarter, compared to analysts' expectations of $12.23 million.
A number of other research analysts have also commented on the stock. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Lake Street Capital cut their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $10.67.
Get Our Latest Research Report on Aquestive Therapeutics
Aquestive Therapeutics Trading Up 2.6%
Shares of AQST traded up $0.06 during mid-day trading on Monday, reaching $2.35. 1,263,613 shares of the stock traded hands, compared to its average volume of 1,516,266. The firm has a fifty day moving average price of $2.71 and a 200 day moving average price of $3.27. The company has a market cap of $233.42 million, a price-to-earnings ratio of -5.22 and a beta of 2.02. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Summit Wealth & Retirement Planning Inc. purchased a new position in Aquestive Therapeutics in the first quarter worth $29,000. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics during the first quarter valued at about $31,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Aquestive Therapeutics during the first quarter valued at about $33,000. New York State Common Retirement Fund boosted its position in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after buying an additional 10,700 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Aquestive Therapeutics during the fourth quarter valued at about $44,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.
Aquestive Therapeutics Company Profile
(
Get Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
See Also
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
